Sickle Cell Gene Therapy Uptake May Lag, But Still Shock State Medicaid Budgets

Medicaid state programs, expected to be the majority payers for the new gene therapies, lack certain flexibilities to help them quickly adapt to high-priced treatments, particularly given the huge jump from current sickle cell treatment costs to the just-approved breakthroughs.